Pandorum Technologies secured 18 million dollars in Series B funding to advance its 3D bioprinting and regenerative medicine pipeline.

Pandorum Technologies

Application

Originally reported by bharatfast.com

Pandorum Technologies secured 18 million dollars in Series B funding to advance its 3D bioprinting and regenerative medicine pipeline. This capital supports the clinical trials of Kuragenx, an FDA-designated liquid cornea therapy. For the AM industry, this signals a critical transition from lab-scale scaffolds to functional, clinical-grade tissue manufacturing. Global partnerships with AGC Biologics and Nucelion will scale this bio-fabrication infrastructure for international markets. 🚀 #3DBioprinting #Biotech #Funding

Explore Pandorum Technologies Read Original

How This Connects

6 related events

Same patternMar 17, 2026
Cyfuse and NSK announce the development of a new bio-3D printer designed for the commercial production of regenerative medicine and 3D cell products.
Same patternFeb 16, 2026
Auxilium Biotechnologies is partnering with Starlab Space to deploy the AMP-1 bioprinting platform for scalable medical manufacturing in low Earth orbit.
Same patternFeb 14, 2026
PrintBio has joined a federal consortium led by WFIRM to receive up to 24.8 million USD from ARPA-H for bioprinting vascularized kidney tissue.
This articleFeb 10, 2026
Pandorum Technologies secured 18 million dollars in Series B funding to advance its 3D bioprinting and regenerative medicine pipeline.
Same patternJan 25, 2026
Carnegie Mellon University secured a 28.5 million dollar ARPA-H award for the LIVE project, developing 3D-printed human liver patches.
Same patternJan 24, 2026
Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes.
Same patternJan 15, 2026
Nanochon secured $4.1M in funding to launch first-in-human trials for its 3D-printed knee implant.